Eli Lilly To Launch Diabetes Drug Byetta In China
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly has received imported drug approval from China's State FDA for its diabetes drug Byetta (exenatide injection), which is expected to be officially launched in China in the second half of this year. Local experts said the drug provides a new option to diabetes patients who cannot achieve good glycemic control with oral anti-diabetic drugs but are averse to insulin injection. Fixed doses of Byetta are easily injected twice daily with a pen device, dispensing with the current inconvenient method of insulin dosage adjustment according to blood sugar levels. Besides controlling blood sugar, the drug also helps patients lose weight; weight gain is a problem plaguing most diabetics. (Click here for more - Chinese Language)
You may also be interested in...
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.